BioSpace News Archive

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced a publication in the peer reviewed, open access journal OncoImmunology of a paper on HB-201,

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a pilot Phase 2 clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19.

Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that it will release interim financial results for the six months ended June 30, 2020 on Tuesday, September 29, 2020 at 7:00 a.m. EDT / 12:00 p.m. BST.

Smith+Nephew, the global medical technology business, welcomes the announcement that its campaign to develop and promote the T.I.M.E. clinical decision support tool 1 was awarded Most Innovative in the category Excellence in Reputation & Thought Leadership at the 2020 Gartner Communications Award Ceremony.

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has received more than 3

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , announced today that John A. Wagner , M.D., Ph.D., has joined the company as chief medical officer (CMO). Since unveiling in 2019 , Cygnal has deepened its executive and scientific leadership. Dr. Wagner is th

First-of-its kind study to be supported by the Cura Foundation, The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin will be participating in a fireside chat and hosting one-on-one meetings at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit , which is being held in a virtual format. The fireside chat is scheduled

-- Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital -- -- Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo -- -- Josh Lehrer joins as CEO -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bio is